Emyria gets green light for final trials of CBD pain-distress treatment

 Synthetic cannabinoid-based product developer Emyria (ASX: EMD) has been given the green light to proceed with a Phase 3 clinical trial of its first ultra-pure CBD candidate, EMD-RX5, in a major milestone for the company.

The trial, supported by Emyria’s clinical service subsidiary Emerald Clinics, is aimed at assessing the efficacy of two dose strengths of EMD-RX5 to treat the psychological distress of patients suffering from chronic pain.

A successful trial will support Emyria’s registration of EMD-RX5 with the Therapeutic Goods Administration as a Schedule 3, over-the-counter treatment.

Read More: https://www.businessnewsaustralia.com/articles/emyria-gets-green-light-for-final-trials-of-cbd-pain-distress-treatment.html



Comments

Popular posts from this blog

THE ULTIMATE BOOKKEEPING CHECKLIST FOR NEW BUSINESSES

WHY BUDGETING IS IMPORTANT FOR BUSINESSES?

Digital business management platform Capsifi names former IDP Education CEO Andrew Barkla as chair